Cover Image

Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core

The use of p53-MDM2 inhibitors is a prospective strategy in anti-cancer therapy for tumors expressing wild type p53 protein. In this study, we have applied a simple approach of two-step synthesis of imidazoline-based alkoxyaryl compounds, which are able to efficiently inhibit p53-MDM2 protein-protei...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniil R. Bazanov (Author), Nikolay V. Pervushin (Author), Egor V. Savin (Author), Michael D. Tsymliakov (Author), Anita I. Maksutova (Author), Victoria Yu. Savitskaya (Author), Sergey E. Sosonyuk (Author), Yulia A. Gracheva (Author), Michael Yu. Seliverstov (Author), Natalia A. Lozinskaya (Author), Gelina S. Kopeina (Author)
Format: Book
Published: MDPI AG, 2022-04-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The use of p53-MDM2 inhibitors is a prospective strategy in anti-cancer therapy for tumors expressing wild type p53 protein. In this study, we have applied a simple approach of two-step synthesis of imidazoline-based alkoxyaryl compounds, which are able to efficiently inhibit p53-MDM2 protein-protein interactions, promote accumulation of p53 and p53-inducible proteins in various cancer cell lines. Compounds <b>2l</b> and <b>2k</b> cause significant upregulation of p53 and p53-inducible proteins in five human cancer cell lines, one of which possesses overexpression of MDM2.
Item Description:10.3390/ph15040444
1424-8247

Similar Items